Table 3.
Univariate and multivariate analysis of factors associated with OS.
| Factors | No. of survival cases | No. of deaths | Univariate analysis for OS | Multivariate analysis for OS | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| Age (year) | 0.105 | – | – | |||
| <50 | 1,047 | 7 | 1 [Reference] | |||
| ≥50 | 1,869 | 25 | 1.98 (0.85–4.57) | |||
| BMI (kg/m2) | 0.544 | – | – | |||
| <25 | 2,134 | 22 | 1 [Reference] | |||
| ≥25 | 782 | 10 | 1.26 (0.60–2.66) | |||
| VFA (cm2) | 0.173 | |||||
| <100 | 1,707 | 15 | 1 [Reference] | |||
| ≥100 | 1,209 | 17 | 1.61 (0.81–3.23) | |||
| ASMI (kg/m2) | 0.036 | 0.049 | ||||
| ≥5.7 | 2,415 | 22 | 1 [Reference] | 1 [Reference] | ||
| <5.7 | 501 | 10 | 2.18 (1.03–4.61) | 2.13 (1.00–4.51) | ||
| Menopausal status | 0.089 | – | – | |||
| Pre/peri-menopausal | 1,161 | 8 | 1 [Reference] | |||
| Post-menopausal | 1,755 | 24 | 1.98 (0.89–4.40) | |||
| History of HTN | 0.943 | – | – | |||
| No | 2,167 | 24 | 1 [Reference] | |||
| Yes | 749 | 8 | 0.97 (0.44–2.16) | |||
| History of DM | 0.109 | – | – | |||
| No | 2,683 | 27 | 1 [Reference] | |||
| Yes | 233 | 5 | 2.14 (0.82–5.56) | |||
| Surgery type | 0.117 | – | – | |||
| Simple mastectomy | 1,864 | 26 | 1 [Reference] | |||
| Breast conservation | 1,005 | 6 | 0.50 (0.35–0.71) | |||
| Others | 47 | 0 | 0.00 (0.00–NA) | |||
| Pathological type | 0.843 | – | – | |||
| IDC | 2,130 | 23 | 1 [Reference] | |||
| Others | 786 | 9 | 1.08 (0.50–2.34) | |||
| Pathological node status | < 0.001 | 0.483 | ||||
| Negative | 2,034 | 12 | 1 [Reference] | 1 [Reference] | ||
| Positive | 882 | 20 | 3.88 (1.90–7.93) | 1.44 (0.52–4.01) | ||
| Clinical tumor stage | < 0.001 | 0.026 | ||||
| T0–1 | 1,448 | 6 | 1 [Reference] | 1 [Reference] | ||
| T2 | 1,098 | 12 | 2.64 (0.99–7.03) | 1.61 (0.51–5.06) | ||
| T3–T4 | 370 | 14 | 9.18 (3.53–23.90) | 4.75 (1.24–18.24) | ||
| AJCC stage | 0.001 | 0.390 | ||||
| I–II | 1,845 | 11 | 1 [Reference] | 1 [Reference] | ||
| III | 1,071 | 21 | 3.28 (1.58–6.80) | 1.43 (0.63–3.24) | ||
| Ki67 status | 0.442 | – | – | |||
| <14% | 914 | 8 | 1 [Reference] | |||
| ≥14% | 2,002 | 24 | 1.37 (0.61–3.04) | |||
| Molecular subtypes | 0.001 | < 0.001 | ||||
| HR+/HER2- | 1,793 | 12 | 1 [Reference] | 1 [Reference] | ||
| HR+/HER2+ | 362 | 1 | 0.42 (0.05–3.21) | 0.28 (0.04–2.19) | ||
| HR-/HER2+ | 391 | 9 | 3.45 (1.46–8.19) | 2.44 (0.97–6.13) | ||
| TNBC | 370 | 10 | 4.10 (1.77–9.48) | 2.77 (1.11–6.88) | ||
| Chemotherapy | 0.005 | 0.395 | ||||
| No | 1,069 | 4 | 1 [Reference] | 1 [Reference] | ||
| Yes | 1,847 | 28 | 3.99 (1.40–11.36) | 1.67 (0.51–5.47) | ||
| Radiotherapy | 0.051 | – | – | |||
| No | 1,323 | 9 | 1 [Reference] | |||
| Yes | 1,593 | 23 | 2.12 (0.98–4.58) | |||
BMI, body mass index; VFA; visceral fat area; ASMI, Appendicular Skeletal Muscle Mass Index; HTN, hypertension; DM, diabetes mellitus; IDC, invasive ductal carcinoma; AJCC, American Joint Committee on Cancer; HR, hormone receptor; HER2, human epithelial growth factor-2; TNBC, triple-negative breast cancer; OS, overall survival; HR, hazard ratio; CI, confidence interval.